#### **PRESS RELEASE**

30 October 2024 14:45:00 CET



# Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024

Today, on 30 October 2024, an extraordinary general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below.

### Election of new board member and remuneration for the new board member

The meeting resolved, in accordance with the proposal from the Nomination Committee, to elect Marianne Kock as new board member for the time period up until the end of the next annual general meeting alongside the board members elected at the annual general meeting held on 6 May 2024.

It was further resolved, in accordance with the proposal from the Nomination Committee, that board remuneration shall be paid with SEK 131,250 to Marianne Kock for the time period up until the end of the next annual general meeting (corresponding to a yearly remuneration of SEK 262,500). In addition, the meeting resolved that any remuneration for committee work to Marianne Kock shall be paid according to the remuneration levels resolved by the annual general meeting 2024 on a pro-rata basis for the remaining time period up until the end of the annual general meeting 2025.

## About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit <a href="http://www.ascelia.com">http://www.ascelia.com</a>.

# Contacts

Magnus Corfitzen, CEO Email: moc@ascelia.com Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)

Email: jwb@ascelia.com Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

## **Attachments**

Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024